Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

U.S. Markets are not yet open, but GILD is being traded in the pre-market session. Pre-Market quote »
101.91
Delayed Data
As of Sep 03
 -2.36 / -2.26%
Today’s Change
85.95
Today|||52-Week Range
123.37
+8.12%
Year-to-Date
Gilead Reports Encouraging Data on TAF-based HIV Regimen
Sep 03 / Zacks.com
Alnylam Presents Positive Data on PCSK9 Synthesis Inhibitor
Aug 31 / Zacks.com
Build a Core Position in Biotech Intrexon at These Lower Prices
Sep 03 / TheStreet.com
3 Stocks Pushing The Health Care Sector Downward
Aug 31 / TheStreet.com
3 Biotech Stocks to Buy in the Middle of a Turbulent Market
Sep 03 / MotleyFool.com
How I Survived the Market Bloodbath Last Week With No Losses
Aug 31 / TheStreet.com
Incyte & Hengrui to Develop Anti-PD-1 Monoclonal Antibody
Sep 03 / Zacks.com
Stock Market News for August 31, 2015
Aug 31 / Zacks.com
AstraZeneca Ties Up for FluMist, CAZ-AVI Scores; Shares Up
Sep 03 / Zacks.com
ARIAD Skyrockets More than 40% Following Buyout Rumors
Aug 31 / Zacks.com
The Zacks Analyst Blog Highlights: Google, Gilead Sciences, Regeneron Pharmaceuticals...
Sep 03 / Zacks.com
4 Not-Too-Scary Ways to Make Money on Biotech Stocks
Aug 30 / MotleyFool.com
Nektar Receives $40M Milestone Payment from AstraZeneca
Sep 03 / Zacks.com
Pfizer (PFE) Gains on Label Expansion Efforts for Ibrance
Aug 28 / Zacks.com
AstraZeneca Strikes Deal with Valeant for Psoriasis Drug
Sep 02 / Zacks.com
Exelixis Up on Swiss Approval of Advanced Melanoma Drug
Aug 28 / Zacks.com
Illumina Acquires GenoLogics, Boosts Genomic Sequencing
Sep 02 / Zacks.com
Eli Lilly's (LLY) Diabetes Drug Synjardy Gets U.S. Approval
Aug 28 / Zacks.com
10 Large-Cap Stocks Favored by Big Institutional Investors
Sep 02 / TheStreet.com
Stock Market News for August 27, 2015
Aug 27 / Zacks.com
4 Google-Beating Stocks that Still Hold Promise
Sep 02 / Zacks.com
J&J to Sell Sugar Substitute Splenda to Heartland Food
Aug 26 / Zacks.com
Strength Seen in Trevena (TRVN): Stock Surges 51.5%
Sep 02 / Zacks.com
Eli Lilly's Alimta Patent Upheld by U.S. District Court
Aug 26 / Zacks.com
Biotech Stock Roundup: Amgen in the News, ARIAD a Takeover Target?
Sep 02 / Zacks.com
Novartis' (NVS) Promacta Label Further Expanded in U.S.
Aug 26 / Zacks.com
5 Top Stocks to Buy in September
Sep 01 / MotleyFool.com
Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review
Aug 26 / Zacks.com
Amicus (FOLD) Signs Agreement to Acquire Scioderm
Sep 01 / Zacks.com
You Can't Keep Volatility Down Forever
Aug 26 / TheStreet.com
Intercept's (ICPT) OCA Under Priority Review in the U.S.
Sep 01 / Zacks.com
Acorda Therapeutics (ACOR) Jumps: Stock Moves 8.3% Higher
Aug 26 / Zacks.com
Trevena's Postoperative Pain Drug Positive in Phase IIb Study
Sep 01 / Zacks.com
Celldex (CLDX) Shows Strength: Stock Adds 8.2% in Session
Aug 26 / Zacks.com
Sanofi Teams Up with Google Life Sciences for Diabetes
Sep 01 / Zacks.com
What Makes CoLucid Pharmaceuticals (CLCD) a Strong Sell?
Aug 26 / Zacks.com
Allergan Buys Naurex, Boosts Mental Health Portfolio
Sep 01 / Zacks.com
4 Notable Stocks Still Green After Late Tuesday Sell-Off
Aug 25 / Zacks.com
Despite Strong U.S. Data, Chinese Economic Woes Weigh on Stocks
Sep 01 / TheStreet.com
Nasdaq Slips into Correction: 4 Stocks Stand Tall
Aug 25 / Zacks.com
Stock Market News for September 01, 2015
Sep 01 / Zacks.com
Medivation to Gain Global Rights to BioMarin's Talazoparib
Aug 25 / Zacks.com
Cytori Therapeutics (CYTX) in Focus: Stock Rises 15%
Sep 01 / Zacks.com
AstraZeneca, Peregrine Team Up for Immuno-Oncology Study
Aug 25 / Zacks.com
BIND Therapeutics (BIND) Rises: Stock Adds 5.4% in Session
Sep 01 / Zacks.com
Bouncing Biotech? 3 Stocks To Buy
Aug 25 / MotleyFool.com
Trade-Ideas: Gilead (GILD) Is Today's Pre-Market Laggard Stock
Sep 01 / TheStreet.com
The Zacks Analyst Blog Highlights: Gilead Sciences, DSW, Cardtronics and CECO Environ...
Aug 25 / Zacks.com
Applied Genetic Meets Enrolment Milestone in XLRS Study
Aug 31 / Zacks.com
Epizyme (EPZM) Shows Strength: Stock Adds 9.6% in Session
Aug 25 / Zacks.com